Cantor Fitzgerald throws some fuel on buyout idea

[jayfish101]

While small molecule candidates will probably account for around 50% of the deals, Cantor says
complex biologics have been gaining in popularity. The bank sees assets such as antibody drug
conjugates, radiopharmaceuticals and T-cell engagers as being particularly attractive acquisition
targets this year, while synthetic lethality and TCR therapies could also see increased interest.
Cantor sees several companies in its coverage universe as potentially attracting suitors this year,
including Kura (NASDAQ:KURA), Bicycle (NASDAQ:BCYC), Immunocore (NASDAQ:IMCR), ALX
Oncology (NASDAQ:ALXO), Arvinas (ARVN), Immatics (IMTX), Verastem (VSTM), Oric (ORIC),
and CG Oncology (NASDAQ:CGON).

Potential targets outside of its coverage include Day One (DAWN), Deciphera (DCPH), Erasca
(ERAS), Exelixis (EXEL), Fusion (FUSN), Geron (GERN), Ideaya (IDYA), Karyopharm (KPTI),
Janux (JANX), Legend Biotech (LEGN), Merus (MRUS), Nuvalent (NUVL), Olmea (OLMA), PMV
(PMVP), Relay Therapeutics(RLAY), Revolution Medicines (RVMD), Syndax (SNDX),
SpringWorks Therapeutics (SWTX), UroGen (URGN), and Zentalis (ZNTL).